Related Experiment Video

Updated: Mar 26, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Recommendations for treating children with drug-resistant tuberculosis

Luisa Galli1, Laura Lancella2, Silvia Garazzino3

  • 1Department of Health Sciences, University of Florence, Pediatric Infectious Diseases Division, Anna Meyer Children's University Hospital, Florence, Italy.

Pharmacological Research
|January 29, 2016
PubMed

Insights

Treating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in children is challenging due to limited pediatric data and drug formulations. Specialized centers are recommended for managing pediatric drug-resistant TB cases.

Area of Science:

  • Infectious Diseases
  • Pediatric Medicine
  • Microbiology

Background:

  • Tuberculosis (TB) remains a significant global health threat, being the second leading cause of death from infectious diseases.
  • Increasing incidence of multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) contributes to high mortality rates.
  • Pediatric TB management is complex due to limited pediatric-specific drug data, unregistered medications, and lack of suitable formulations for young children.

Purpose of the Study:

  • To outline recommendations for the therapeutic approach to pediatric MDR-TB and XDR-TB.
  • To address the challenges in treating drug-resistant TB in children.
  • To provide guidance for healthcare professionals managing pediatric TB cases.

Main Methods:

  • Systematic literature review of existing pediatric TB treatment data.
  • Incorporation of clinical experience from a group of scientific societies.
  • Development of expert recommendations for therapeutic strategies.

Main Results:

  • Drug-resistant TB in children presents unique management difficulties.
  • Many effective anti-TB drugs lack pediatric registration and suitable formulations.
  • Second-line anti-TB treatments are associated with significant adverse events, requiring careful monitoring.

Conclusions:

  • Children with active drug-resistant TB require referral to specialized centers for expert management.
  • The complexity of pediatric drug-resistant TB necessitates a multidisciplinary and experienced approach.
  • Further research and development of pediatric-specific TB treatments are crucial.

Keywords:
Anti-tuberculosis drugsChildrenMDR-TBPediatric tuberculosisXDR-TB

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
768
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
370
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
632
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
328
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
733